IGH/MYC Translocation Associates With BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors

Molecular Cancer Research - United States
doi 10.1158/1541-7786.mcr-16-0468
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Drugging RB1 Deficiency: Synthetic Lethality With Aurora Kinases

Cancer Discovery
Oncology
2019English

C-Myc Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality With TRAIL.

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

KEAP1-Dependent Synthetic Lethality Induced by AKT and TXNRD1 Inhibitors in Lung Cancer

Cancer Research
Cancer ResearchOncology
2013English

A Rare Case of IGH/MYC and IGH/BCL2 Double Hit Primary Plasma Cell Leukemia

Haematologica
Hematology
2014English

Candidate Synthetic Lethality Partners to PARP Inhibitors in the Treatment of Ovarian Clear Cell Cancer (Review)

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2017English

Targeting PARP1 in XRCC1 Deficient Sporadic Invasive Breast Cancer or Pre-Invasive Ductal Carcinoma in Situ Induces Synthetic Lethality and Chemoprevention

Cancer Research
Cancer ResearchOncology
2018English

Long-Range Oncogenic Activation of Igh–c-Myc Translocations by the Igh 3′ Regulatory Region

Nature
Multidisciplinary
2009English

The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality Through PARP Inhibition

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2019English

Genome-Wide RNAi to Identify Genes That Confer Synthetic Lethality With BRCA1

Breast Cancer Research
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy